In 2020, Kelly et al. reported RPS-085 ligand, capable of both PSMA and serum albumin binding, and a theranostic approach based on 64Cu/67Cu pair for prostate cancer therapy and imaging (Figure 4) [92]. The gene discussed is FOLH1; the disease is prostate cancer.